ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

HIK Hikma Pharmaceuticals Plc

1,918.50
38.00 (2.02%)
28 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Hikma Pharmaceuticals Plc LSE:HIK London Ordinary Share GB00B0LCW083 ORD SHS 10P
  Price Change % Change Share Price Shares Traded Last Trade
  38.00 2.02% 1,918.50 504,022 16:35:27
Bid Price Offer Price High Price Low Price Open Price
1,925.00 1,927.00 1,937.50 1,887.50 1,903.00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations USD 2.88B USD 190M USD 0.8594 22.41 4.26B
Last Trade Time Trade Type Trade Size Trade Price Currency
18:10:10 O 5,288 1,922.798 GBX

Hikma Pharmaceuticals (HIK) Latest News

Hikma Pharmaceuticals (HIK) Discussions and Chat

Hikma Pharmaceuticals Forums and Chat

Date Time Title Posts
22/3/202420:32Hikma Pharmaceuticals1,762
13/1/201515:12 *** Hikma ***98

Add a New Thread

Hikma Pharmaceuticals (HIK) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2024-03-28 18:10:251,922.805,288101,677.56O
2024-03-28 18:10:251,906.501462,783.49O
2024-03-28 18:09:071,923.877,386142,097.26O
2024-03-28 18:07:341,923.236,907132,837.57O
2024-03-28 17:56:031,918.5020,869400,371.77O

Hikma Pharmaceuticals (HIK) Top Chat Posts

Top Posts
Posted at 28/3/2024 08:20 by Hikma Pharmaceuticals Daily Update
Hikma Pharmaceuticals Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker HIK. The last closing price for Hikma Pharmaceuticals was 1,880.50p.
Hikma Pharmaceuticals currently has 221,081,676 shares in issue. The market capitalisation of Hikma Pharmaceuticals is Ā£4,258,033,080.
Hikma Pharmaceuticals has a price to earnings ratio (PE ratio) of 22.41.
This morning HIK shares opened at 1,903p
Posted at 13/1/2024 21:31 by hopeful holder
So far, HIK has proven to be better even over this short period.
Posted at 30/8/2023 07:57 by robertball
Not caught by Us drug announcement yesterday re price controls...
Posted at 28/4/2023 08:13 by robertball
I'm here. This share is overlooked. Sigi's resignation was a bit of a blow and appointing an internal candidate was a vote of no confidence.It's a family firm and it might do OK in the long term.Not for speculators
Posted at 02/3/2023 19:01 by ariane
Iain Gilbert
Sharecast News
27 Feb, 2023 16:26 27 Feb, 2023 16:27


Broker tips: Hikma Pharmaceuticals


Analysts at Berenberg raised their target price on drugmaker Hikma Pharmaceuticals from 1,440.0p to 1,740.0p on Monday on the back of the group's recent trading update.

Berenberg stated that last week, Hikma reported "decent" 2022 results, in its view, with no real changes to the group's outlook from January when management presented at a competitor conference.
Posted at 02/3/2023 17:43 by waldron
RBC raises Hikma Pharma price target to 1,950 (1,750) pence - 'outperform'
Posted at 08/2/2023 13:45 by adamb1978
Share price has had a nice run over the last 3-4 months however is still very cheap if you believe it can grow at mid single digit %s which market forecasts suggest and generate the 20%-ish ROCE which it historically has.

If you believe in mean reversion and see it getting back to multiples over the last few years, this should be heading to £25-£30
Posted at 30/9/2022 09:32 by cumnor
Bought in here at £13 avg. Now the diversity nonsense is out of the way these guys (and gals I suppose) need to up the ante on their dividend payments if they wish to recover the share price.....
Posted at 15/9/2022 11:01 by swinsco
Jeffries have just cut Hik price target to 2020 from 2200 and keep it a buy rating. Broker nonsense!
Posted at 18/8/2022 19:32 by cumnor
Punters and IIs are tiring of indebted companies like Hikma which paid divis of 2% for past couple of years, promised the earth and fail to deliver, as recent results show. Meanwhile directors pay themselves huge salaries and bonuses but expect investors to pay dear for the measly dividend. This could have been more generous and the recent falls (not just here) in poor payers share prices reflect a change in attitude to greedy directors.
Needs to see a divi of 5% plus before I'd touch this.
Posted at 04/8/2022 09:06 by adamb1978
Even taking historic earnings, PE is only around 11x. It feels like there's a lot of negativity built into the share price here. To justify this sort of multiple, you need to believe that the business is going to be more of less flat going forwards

No investment is a sure thing, and they're all an assessment of upside and downside potential. It feels to me that the multiple provides for a lot of downside protection here, and probably far too much
Hikma Pharmaceuticals share price data is direct from the London Stock Exchange

Your Recent History

Delayed Upgrade Clock